Letter: infliximab concentrations during induction therapy-one size does not fit all.
作者信息
Papamichael K, Cheifetz A S
机构信息
Division of Gastroenterology, Center for Inflammatory Bowel Diseases, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
出版信息
Aliment Pharmacol Ther. 2018 May;47(9):1334-1335. doi: 10.1111/apt.14616.
Abstract
摘要
相似文献
1
Letter: infliximab concentrations during induction therapy-one size does not fit all.信函：诱导治疗期间英夫利昔单抗的浓度——并非一刀切
Aliment Pharmacol Ther. 2018 May;47(9):1334-1335. doi: 10.1111/apt.14616.
2
Letter: addition of azathioprine to infliximab maintenance therapy in patients with anti-drug antibodies and subclinical inflammation.
Aliment Pharmacol Ther. 2018 Feb;47(4):544-545. doi: 10.1111/apt.14472.
3
Methotrexate for induction of remission in refractory Crohn's disease.甲氨蝶呤用于诱导难治性克罗恩病缓解
Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459. doi: 10.1002/14651858.CD003459.pub3.
4
Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.比较免疫抑制剂和生物制剂在诱导和维持克罗恩病缓解方面的疗效：一项网络荟萃分析。
Gastroenterology. 2015 Feb;148(2):344-54.e5; quiz e14-5. doi: 10.1053/j.gastro.2014.10.011. Epub 2014 Oct 16.
5
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study.在克罗恩病患者中，使用硫唑嘌呤或英夫利昔单抗预防术后复发：一项开放标签的初步研究。
J Crohns Colitis. 2013 Dec;7(12):e623-9. doi: 10.1016/j.crohns.2013.04.020. Epub 2013 Jun 27.
6
Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.硫唑嘌呤与英夫利昔单抗联合治疗期间红细胞平均体积的变化与黏膜愈合相关：来自SONIC研究的事后分析
Inflamm Bowel Dis. 2015 Mar;21(3):606-14. doi: 10.1097/MIB.0000000000000302.
7
Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro.英夫利昔单抗诱导的调节性巨噬细胞参与体内和体外的愈合过程。
Inflamm Bowel Dis. 2012 Mar;18(3):401-8. doi: 10.1002/ibd.21818. Epub 2011 Sep 20.
8
Infliximab and azathioprine: bridge or parachute?英夫利昔单抗和硫唑嘌呤：桥梁还是降落伞？
Gastroenterology. 2006 Apr;130(4):1354-7. doi: 10.1053/j.gastro.2006.02.038.
9
Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?在克罗恩病中，抗TNF药物与免疫抑制药物联合使用是否有益？是利还是弊？
Rev Recent Clin Trials. 2009 Sep;4(3):152-8. doi: 10.2174/157488709789957664.
10
Infliximab- and azathioprine-related severe neutropenia and thrombocytopenia in a case with Crohn's disease.1例克罗恩病患者出现英夫利昔单抗和硫唑嘌呤相关的严重中性粒细胞减少和血小板减少
Turk J Gastroenterol. 2011 Oct;22(5):537-9. doi: 10.4318/tjg.2011.0409.
引用本文的文献
1
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.炎症性肠病生物制剂的治疗药物监测：未满足的需求和未来展望。
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):171-185. doi: 10.1016/S2468-1253(21)00223-5.
2
Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.维持阿达木单抗浓度与炎症性肠病的生化、内镜和组织学缓解相关。
Dig Dis Sci. 2018 Nov;63(11):3067-3073. doi: 10.1007/s10620-018-5202-5. Epub 2018 Jul 13.
本文引用的文献
1
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.早期药物和抗英夫利昔单抗抗体水平预测英夫利昔单抗治疗原发性无应答。
Aliment Pharmacol Ther. 2018 Jan;47(2):212-218. doi: 10.1111/apt.14410. Epub 2017 Nov 9.
2
Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.在炎症性肠病中诱导抗肿瘤坏死因子治疗期间的治疗药物监测：定义治疗药物窗口。
Inflamm Bowel Dis. 2017 Sep;23(9):1510-1515. doi: 10.1097/MIB.0000000000001231.
3
Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.诱导 infliximab 水平与肛周克罗恩病临床应答的相关性。
J Crohns Colitis. 2017 May 1;11(5):549-555. doi: 10.1093/ecco-jcc/jjw182.
4
Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?生物类似物英夫利昔单抗治疗的短期和中期疗效预测。是药物谷浓度和抗药物抗体水平还是临床和生化标志物发挥更重要的作用？
J Crohns Colitis. 2017 Jun 1;11(6):697-705. doi: 10.1093/ecco-jcc/jjw203.
5
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.英夫利昔单抗诱导治疗期间的浓度阈值与溃疡性结肠炎患者的短期黏膜愈合相关。
Clin Gastroenterol Hepatol. 2016 Apr;14(4):543-9. doi: 10.1016/j.cgh.2015.11.014. Epub 2015 Dec 8.
6
Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.在中重度溃疡性结肠炎患者中，药代动力学特征和抗药物抗体的存在与英夫利昔单抗诱导治疗的应答相关。
Clin Gastroenterol Hepatol. 2016 Feb;14(2):251-8.e1-2. doi: 10.1016/j.cgh.2015.10.029. Epub 2015 Nov 9.
7
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.英夫利昔单抗第2周的首次谷浓度可预测溃疡性结肠炎诱导治疗的未来结局——一项多中心前瞻性随机对照试验及其事后分析的结果
J Gastroenterol. 2016 Mar;51(3):241-51. doi: 10.1007/s00535-015-1102-z. Epub 2015 Jul 11.
8
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.英夫利昔单抗血清浓度与溃疡性结肠炎成年患者疗效的相关性。
Gastroenterology. 2014 Dec;147(6):1296-1307.e5. doi: 10.1053/j.gastro.2014.08.035. Epub 2014 Aug 28.
9
Antibody response to infliximab and its impact on pharmacokinetics can be transient.英夫利昔单抗的抗体应答及其对药代动力学的影响可能是短暂的。
Am J Gastroenterol. 2013 Jun;108(6):962-71. doi: 10.1038/ajg.2013.12. Epub 2013 Feb 19.
Zotero 插件